Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Emgality
Marketing
Eli Lilly hit by migraine drug launch slowdown, but rivals jump
As the dust settles around pharma’s second-quarter financial readouts, we check in on how the new and increasingly crowded migraine market is looking.
Ben Adams
Aug 5, 2022 11:58am
Lilly finds stigma is one of the top problems for migraine
Jun 22, 2022 7:50am
Biohaven looks to expand migraine drug Nurtec to rhinosinusitis
Feb 22, 2022 11:16am
Biohaven's Nurtec ODT continued to roll in 2021
Jan 6, 2022 10:33am
Despite pharma DTC blitz migraine meds lack recognition: survey
Nov 21, 2021 7:05am
Lilly launches Emgality-Nurtec head-to-head trial
Nov 18, 2021 11:48am
